We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
- Authors
Delabaudière, Cyrielle; Lavayssière, Laurence; Dörr, Gaëlle; Muscari, Fabrice; Danjoux, Marie; Sallusto, Federico; Peron, Jean Marie; Bureau, Christophe; Rostaing, Lionel; Izopet, Jacques; Kamar, Nassim
- Abstract
Fibrosing cholestatic hepatitis ( FCH) is a classical but rare and severe form of recurrent hepatitis C virus ( HCV) after liver transplantation. Classical anti- HCV therapy, that is pegylated-interferon (peg-interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg-interferon, ribavirin, plus sofosbuvir to treat HCV-induced FCH in a combined liver-kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir-based anti- HCV therapy can be successfully used to treat FCH after a liver or combined kidney-liver transplantation.
- Subjects
LIVER transplantation; INTERFERONS; ANTIMETABOLITES; ANTIVIRAL agents; BILIARY tract; INFLAMMATION
- Publication
Transplant International, 2015, Vol 28, Issue 2, p255
- ISSN
0934-0874
- Publication type
Article
- DOI
10.1111/tri.12428